266 related articles for article (PubMed ID: 20569502)
1. Dynamic changes in gene expression in vivo predict prognosis of tamoxifen-treated patients with breast cancer.
Taylor KJ; Sims AH; Liang L; Faratian D; Muir M; Walker G; Kuske B; Dixon JM; Cameron DA; Harrison DJ; Langdon SP
Breast Cancer Res; 2010; 12(3):R39. PubMed ID: 20569502
[TBL] [Abstract][Full Text] [Related]
2. Microarray data analysis in neoadjuvant biomarker studies in estrogen receptor-positive breast cancer.
Luo J; Ellis MJ
Breast Cancer Res; 2010; 12(4):112. PubMed ID: 20804563
[TBL] [Abstract][Full Text] [Related]
3. Trefoil factor 3 is oncogenic and mediates anti-estrogen resistance in human mammary carcinoma.
Kannan N; Kang J; Kong X; Tang J; Perry JK; Mohankumar KM; Miller LD; Liu ET; Mertani HC; Zhu T; Grandison PM; Liu DX; Lobie PE
Neoplasia; 2010 Dec; 12(12):1041-53. PubMed ID: 21170268
[TBL] [Abstract][Full Text] [Related]
4. Network-based approach to identify prognosis-related genes in tamoxifen-treated patients with estrogen receptor-positive breast cancer.
Wang Y; Gong X; Zhang Y
Biosci Rep; 2021 Sep; 41(9):. PubMed ID: 34406386
[TBL] [Abstract][Full Text] [Related]
5. Acquired resistance to endocrine treatments is associated with tumor-specific molecular changes in patient-derived luminal breast cancer xenografts.
Cottu P; Bièche I; Assayag F; El Botty R; Chateau-Joubert S; Thuleau A; Bagarre T; Albaud B; Rapinat A; Gentien D; de la Grange P; Sibut V; Vacher S; Hatem R; Servely JL; Fontaine JJ; Decaudin D; Pierga JY; Roman-Roman S; Marangoni E
Clin Cancer Res; 2014 Aug; 20(16):4314-25. PubMed ID: 24947930
[TBL] [Abstract][Full Text] [Related]
6. Widespread estrogen-dependent repression of micrornas involved in breast tumor cell growth.
Maillot G; Lacroix-Triki M; Pierredon S; Gratadou L; Schmidt S; Bénès V; Roché H; Dalenc F; Auboeuf D; Millevoi S; Vagner S
Cancer Res; 2009 Nov; 69(21):8332-40. PubMed ID: 19826037
[TBL] [Abstract][Full Text] [Related]
7. Changes in expression of oestrogen regulated and proliferation genes with neoadjuvant treatment highlight heterogeneity of clinical resistance to the aromatase inhibitor, letrozole.
Miller WR; Larionov A
Breast Cancer Res; 2010; 12(4):R52. PubMed ID: 20646288
[TBL] [Abstract][Full Text] [Related]
8. Proliferation and estrogen signaling can distinguish patients at risk for early versus late relapse among estrogen receptor positive breast cancers.
Bianchini G; Pusztai L; Karn T; Iwamoto T; Rody A; Kelly C; Müller V; Schmidt S; Qi Y; Holtrich U; Becker S; Santarpia L; Fasolo A; Del Conte G; Zambetti M; Sotiriou C; Haibe-Kains B; Symmans WF; Gianni L
Breast Cancer Res; 2013; 15(5):R86. PubMed ID: 24060333
[TBL] [Abstract][Full Text] [Related]
9. Estrogen regulation in human breast cancer cells of new downstream gene targets involved in estrogen metabolism, cell proliferation and cell transformation.
Vendrell JA; Magnino F; Danis E; Duchesne MJ; Pinloche S; Pons M; Birnbaum D; Nguyen C; Theillet C; Cohen PA
J Mol Endocrinol; 2004 Apr; 32(2):397-414. PubMed ID: 15072547
[TBL] [Abstract][Full Text] [Related]
10. Altered expression of estrogen-regulated genes in a tamoxifen-resistant and ICI 164,384 and ICI 182,780 sensitive human breast cancer cell line, MCF-7/TAMR-1.
Lykkesfeldt AE; Madsen MW; Briand P
Cancer Res; 1994 Mar; 54(6):1587-95. PubMed ID: 8137264
[TBL] [Abstract][Full Text] [Related]
11. Development of resistance to targeted therapies transforms the clinically associated molecular profile subtype of breast tumor xenografts.
Creighton CJ; Massarweh S; Huang S; Tsimelzon A; Hilsenbeck SG; Osborne CK; Shou J; Malorni L; Schiff R
Cancer Res; 2008 Sep; 68(18):7493-501. PubMed ID: 18794137
[TBL] [Abstract][Full Text] [Related]
12. Transient over-expression of estrogen receptor-α in breast cancer cells promotes cell survival and estrogen-independent growth.
Tolhurst RS; Thomas RS; Kyle FJ; Patel H; Periyasamy M; Photiou A; Thiruchelvam PT; Lai CF; Al-Sabbagh M; Fisher RA; Barry S; Crnogorac-Jurcevic T; Martin LA; Dowsett M; Charles Coombes R; Kamalati T; Ali S; Buluwela L
Breast Cancer Res Treat; 2011 Jul; 128(2):357-68. PubMed ID: 20730598
[TBL] [Abstract][Full Text] [Related]
13. Estrogen-induced circRNA, circPGR, functions as a ceRNA to promote estrogen receptor-positive breast cancer cell growth by regulating cell cycle-related genes.
Wang L; Yi J; Lu LY; Zhang YY; Wang L; Hu GS; Liu YC; Ding JC; Shen HF; Zhao FQ; Huang HH; Liu W
Theranostics; 2021; 11(4):1732-1752. PubMed ID: 33408778
[TBL] [Abstract][Full Text] [Related]
14. Tamoxifen resistance alters sensitivity to 5-fluorouracil in a subset of estrogen receptor-positive breast cancer.
Watanabe T; Oba T; Tanimoto K; Shibata T; Kamijo S; Ito KI
PLoS One; 2021; 16(6):e0252822. PubMed ID: 34101751
[TBL] [Abstract][Full Text] [Related]
15. A new class of small molecule estrogen receptor-alpha antagonists that overcome anti-estrogen resistance.
Ma Y; Preet A; Tomita Y; De Oliveira E; Zhang L; Ueda Y; Clarke R; Brown M; Rosen EM
Oncotarget; 2015 Dec; 6(38):40388-404. PubMed ID: 26575173
[TBL] [Abstract][Full Text] [Related]
16. Tissue-specific pathways for estrogen regulation of ovarian cancer growth and metastasis.
Spillman MA; Manning NG; Dye WW; Sartorius CA; Post MD; Harrell JC; Jacobsen BM; Horwitz KB
Cancer Res; 2010 Nov; 70(21):8927-36. PubMed ID: 20959477
[TBL] [Abstract][Full Text] [Related]
17. ER alpha negative breast cancer cells restore response to endocrine therapy by combination treatment with both HDAC inhibitor and DNMT inhibitor.
Fan J; Yin WJ; Lu JS; Wang L; Wu J; Wu FY; Di GH; Shen ZZ; Shao ZM
J Cancer Res Clin Oncol; 2008 Aug; 134(8):883-90. PubMed ID: 18264725
[TBL] [Abstract][Full Text] [Related]
18. Co-Expression Effect of SLC7A5/SLC3A2 to Predict Response to Endocrine Therapy in Oestrogen-Receptor-Positive Breast Cancer.
Alfarsi LH; El-Ansari R; Craze ML; Masisi BK; Mohammed OJ; Ellis IO; Rakha EA; Green AR
Int J Mol Sci; 2020 Feb; 21(4):. PubMed ID: 32093034
[TBL] [Abstract][Full Text] [Related]
19. Anterior gradient-2 plays a critical role in breast cancer cell growth and survival by modulating cyclin D1, estrogen receptor-alpha and survivin.
Vanderlaag KE; Hudak S; Bald L; Fayadat-Dilman L; Sathe M; Grein J; Janatpour MJ
Breast Cancer Res; 2010; 12(3):R32. PubMed ID: 20525379
[TBL] [Abstract][Full Text] [Related]
20. Proteomic and transcriptomic profiling reveals a link between the PI3K pathway and lower estrogen-receptor (ER) levels and activity in ER+ breast cancer.
Creighton CJ; Fu X; Hennessy BT; Casa AJ; Zhang Y; Gonzalez-Angulo AM; Lluch A; Gray JW; Brown PH; Hilsenbeck SG; Osborne CK; Mills GB; Lee AV; Schiff R
Breast Cancer Res; 2010; 12(3):R40. PubMed ID: 20569503
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
